title: [Atypical neuroleptics in the child and adolescent].
abstract: The FDA approval for clozapine in 1990 under several hematologic surveillance conditions has reactualized the debate on the use of atypical neuroleptics for adults with schizophrenia. The use of conventional neuroleptics in children and adolescents has always been a subject of controversy due to their side effects and the absence of controlled studies. The pharmacological action of clozapine and risperidone is mainly on D2 and 5HT. Since 1992 several studies concerning children and adolescents show the efficiency and the tolerance of the clozapine and risperidone in various disorders, especially in very early onset schizophrenia (VEOS). Controlled trials are necessary to confirm the data obtained in open studies.
authors.affiliation: Interne Service de Psychopathologie de l'Enfant et de l'Adolescent, Hôpital Robert Debré, Paris.
authors.forename: W J
authors.initials: WJ
authors.lastname: Naja
authors.forename: J P
authors.initials: JP
authors.lastname: Reneric
authors.forename: M P
authors.initials: MP
authors.lastname: Bouvard
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003024:Clozapine / Q000008:administration & dosage* / Q000009:adverse effects; D016903:Drug Monitoring; D006801:Humans; D018967:Risperidone / Q000008:administration & dosage* / Q000009:adverse effects; D012561:Schizophrenia, Childhood / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine; D018967:Risperidone